source
- MapLight’s schizophrenia drug misses primary endpoint in Phase 2, shares tumble over 60%MapLight Therapeutics reported results from a mid‑stage Phase 2 trial of its experimental schizophrenia therapy. The study evaluated a once‑daily dosing regimen and failed to meet the predefined p…
- Gossamer ends $486M PAH partnership with Chiesi after phase 3 missGossamer Bio announced it is terminating its collaboration and licensing agreement with Italy's Chiesi, regaining worldwide development and commercial rights to its pulmonary arterial hypertension…